4.5 Article

Safety and Tolerability Associated With Second-Generation Antipsychotic Polytherapy in Bipolar Disorder: Findings From the Systematic Treatment Enhancement Program for Bipolar Disorder

期刊

JOURNAL OF CLINICAL PSYCHIATRY
卷 72, 期 2, 页码 240-247

出版社

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.09m05214yel

关键词

-

资金

  1. NIMH [K-23, MH01936]
  2. NIMH, National Institutes of Health [N01MH80001]
  3. AstraZeneca
  4. Cephalon
  5. Eli Lilly
  6. Pfizer
  7. Abbott
  8. GlaxoSmithKline
  9. Janssen
  10. Bristol-Myers Squibb
  11. Elan
  12. Lilly Research
  13. Parke Davis
  14. R. W. Johnson Pharmaceutical Institute
  15. Smith Kline Beecham
  16. Stanley Medical Research Foundation

向作者/读者索取更多资源

Context: Practitioners often combine 2 or more second-generation antipsychotics (SGAs) in patients with bipolar disorder, despite an absence of data to support their safety, tolerability, or efficacy. Objective: This study sought to evaluate the safety and tolerability of SGA polytherapy compared to SGA monotherapy in bipolar disorder patients receiving open naturalistic treatment in the 22-site Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Method: A longitudinal cohort of 1,958 patients who were prescribed at least 1 SGA was drawn from 4,035 bipolar patients in STEP-BD recruited between November 1999 and July 2005 and assessed at least quarterly for a mean duration of 21 months. Main outcome measures were the mean quarterly prevalence of adverse events, medical and psychiatric service usage, Global Assessment of Functioning ratings, and percentage of days spent well. Results: Almost 10% of patients taking SGAs were prescribed SGA polytherapy. After controlling for illness onset, age, baseline illness severity, and medication load, patients prescribed SGA polytherapy, compared to monotherapy, exhibited more dry mouth (number needed to harm [NNH] = 4), tremor (NNH = 6), sedation (NNH = 8), sexual dysfunction (NNH = 8), and constipation (NNH = 11) and were almost 3 times as likely to incur more psychiatric and medical care; there was no association with greater global functioning scores or percentage of days spent well. Conclusions: Although SGA polytherapy was fairly common in bipolar disorder, it was associated with increased side effects and health service use but not with improved clinical status or function. Thus, SGA polytherapy in bipolar disorder may incur important disadvantages without clear benefit, warranting careful consideration before undertaking such interventions. J Clin Psychiatry 2011;72(2):240-247 (C) Copyright 2010 Physicians Postgraduate Press, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据